Literature DB >> 15976883

Availability of miltefosine for the treatment of kala-azar in India.

Shyam Sundar1, Henry W Murray.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15976883      PMCID： PMC2626237          DOI： /S0042-96862005000500018

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN： 0042-9686            Impact factor:   9.408


× No keyword cloud information.
  35 in total

1.  Evaluation of arylimidamides DB1955 and DB1960 as candidates against visceral leishmaniasis and Chagas' disease: in vivo efficacy, acute toxicity, pharmacokinetics, and toxicology studies.

Authors:  Xiaohua Zhu; Qiang Liu; Sihyung Yang; Toufan Parman; Carol E Green; Jon C Mirsalis; Maria de Nazaré Correia Soeiro; Elen Mello de Souza; Cristiane França da Silva; Denise da Gama Jaen Batista; Chad E Stephens; Moloy Banerjee; Abdelbasset A Farahat; Manoj Munde; W David Wilson; David W Boykin; Michael Zhuo Wang; Karl A Werbovetz
Journal:  Antimicrob Agents Chemother       Date:  2012-04-16       Impact factor: 5.191

2.  Downregulation of mitogen-activated protein kinase 1 of Leishmania donovani field isolates is associated with antimony resistance.

Authors:  Mansi Garg; Shyam Sundar; Robert Duncan; Hira L Nakhasi; Neena Goyal
Journal:  Antimicrob Agents Chemother       Date:  2011-11-07       Impact factor: 5.191

3.  Effectiveness and safety of liposomal amphotericin B for visceral leishmaniasis under routine program conditions in Bihar, India.

Authors:  Prabhat K Sinha; Paul Roddy; Pedro Pablo Palma; Alice Kociejowski; María Angeles Lima; Vidya Nand Rabi Das; Jitendra Gupta; Nawin Kumar; Gaurab Mitra; Jean-François Saint-Sauveur; Siju Seena; Manica Balasegaram; Fernando Parreño; Krishna Pandey
Journal:  Am J Trop Med Hyg       Date:  2010-08       Impact factor: 2.345

4.  In vitro and in vivo interactions between miltefosine and other antileishmanial drugs.

Authors:  Karin Seifert; Simon L Croft
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

5.  Intestinal absorption of miltefosine: contribution of passive paracellular transport.

Authors:  Cécile Ménez; Marion Buyse; Christophe Dugave; Robert Farinotti; Gillian Barratt
Journal:  Pharm Res       Date:  2007-03       Impact factor: 4.200

6.  In vitro susceptibility of field isolates of Leishmania donovani to Miltefosine and amphotericin B: correlation with sodium antimony gluconate susceptibility and implications for treatment in areas of endemicity.

Authors:  Dhiraj Kumar; Arpita Kulshrestha; Ruchi Singh; Poonam Salotra
Journal:  Antimicrob Agents Chemother       Date:  2008-11-17       Impact factor: 5.191

Review 7.  Drug resistance in leishmaniasis.

Authors:  Simon L Croft; Shyam Sundar; Alan H Fairlamb
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

8.  Alteration of the serum biomarker profiles of visceral leishmaniasis during treatment.

Authors:  M S Duthie; J Guderian; A Vallur; A Bhatia; P Lima dos Santos; E Vieira de Melo; A Ribeiro de Jesus; M Todt; D Mondal; R Almeida; S G Reed
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-10-31       Impact factor: 3.267

9.  Efficacy of orally administered 2-substituted quinolines in experimental murine cutaneous and visceral leishmaniases.

Authors:  Hector Nakayama; Philippe M Loiseau; Christian Bories; Susana Torres de Ortiz; Alicia Schinini; Elsa Serna; Antonieta Rojas de Arias; Mohamed A Fakhfakh; Xavier Franck; Bruno Figadère; Reynald Hocquemiller; Alain Fournet
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

10.  Drug resistance in leishmaniasis.

Authors:  Jaya Chakravarty; Shyam Sundar
Journal:  J Glob Infect Dis       Date:  2010-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.